

Dr. Streck succeeds Alder's interim CMO, Eric Carter who has been responsible for leading the preparation of the Biologics License Application (BLA) for eptinezumab and ensuring its submission in the first quarter of 2019. Dr. Carter will continue to work closely with the company as a consultant following the transition.

Bob Azelby said, “Paul brings extensive experience with regulatory interactions, clinical trial execution, and product lifecycle management, as well as leading medical affairs organizations, and we are delighted to welcome him to the Alder team. This experience, coupled with his deep operating expertise, will be highly valuable as we continue to engage with the U.S. Food and Drug Administration (FDA), including through our planned BLA submission for eptinezumab later this quarter, and to build out our medical and commercial infrastructure in anticipation of the potential launch in the first quarter of 2020.”

“I’m excited to join Alder’s strong leadership team and have been inspired by the company’s commitment to transform the treatment paradigm for millions of patients debilitated by migraine. This is an important time for Alder and for migraine patients. I look forward to working with the Alder team to ensure the successful approval and launch of eptinezumab and the growth of Alder as a leader in novel migraine therapeutics”, said Dr. Streck.

Streck received his medical degree from Jefferson Medical College. He also holds a doctor of dental medicine degree from Temple University’s School of Dentistry, and a master’s of business administration from Fuqua School of Business at Duke University.